Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: DRUG: epirubicin hydrochloride|DRUG: Cyclophosphamide|DRUG: Albumin bound paclitaxel|DRUG: Toripalimab
Sponsor: Fudan University